Evidence map›Paper›PMID 36240068›Full record

ArticleThe Biochemical journal2022

Claspin haploinsufficiency leads to defects in fertility, hyperplasia and an increased oncogenic potential.

Suzanne Madgwick, Saimir Luli, Helene Sellier, Jacqueline A Butterworth, Jack Leslie, Adam J Moore, Emma K Corbin, Adrian I Yemm, Robson T Chiremba, Dina Tiniakos and 3 more

Open access · hybridAbstract read
In one paragraph

Article in The Biochemical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Claspin and Cancer: Where Are We Now?International journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Suzanne MadgwickNewcastle University Biosciences Institute, Wolfson Childhood Cancer Research Centre, Level 6, Herschel Building, Newcastle University, Brewery Lane, Newcastle upon Tyne NE1 7RU, U.K.
Saimir LuliPreclinical In Vivo Imaging Facility, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne NE2 4HH, U.K.
Helene SellierNewcastle University Biosciences Institute, Wolfson Childhood Cancer Research Centre, Level 6, Herschel Building, Newcastle University, Brewery Lane, Newcastle upon Tyne NE1 7RU, U.K.
Jacqueline A ButterworthNewcastle University Biosciences Institute, Wolfson Childhood Cancer Research Centre, Level 6, Herschel Building, Newcastle University, Brewery Lane, Newcastle upon Tyne NE1 7RU, U.K.
Jack LeslieNewcastle Fibrosis Research Group, Newcastle University Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne NE2 4HH, U.K.
Adam J MooreNewcastle University Biosciences Institute, Wolfson Childhood Cancer Research Centre, Level 6, Herschel Building, Newcastle University, Brewery Lane, Newcastle upon Tyne NE1 7RU, U.K.
Emma K CorbinNewcastle University Biosciences Institute, Wolfson Childhood Cancer Research Centre, Level 6, Herschel Building, Newcastle University, Brewery Lane, Newcastle upon Tyne NE1 7RU, U.K.
Adrian I YemmNewcastle University Biosciences Institute, Wolfson Childhood Cancer Research Centre, Level 6, Herschel Building, Newcastle University, Brewery Lane, Newcastle upon Tyne NE1 7RU, U.K.
Robson T ChirembaNewcastle University Biosciences Institute, Wolfson Childhood Cancer Research Centre, Level 6, Herschel Building, Newcastle University, Brewery Lane, Newcastle upon Tyne NE1 7RU, U.K.
Dina TiniakosNewcastle Fibrosis Research Group, Newcastle University Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne NE2 4HH, U.K.
Fiona OakleyNewcastle Fibrosis Research Group, Newcastle University Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne NE2 4HH, U.K.
Neil D PerkinsNewcastle University Biosciences Institute, Wolfson Childhood Cancer Research Centre, Level 6, Herschel Building, Newcastle University, Brewery Lane, Newcastle upon Tyne NE1 7RU, U.K.ORCID 0000-0002-9756-3656
Jill E HunterNewcastle University Biosciences Institute, Wolfson Childhood Cancer Research Centre, Level 6, Herschel Building, Newcastle University, Brewery Lane, Newcastle upon Tyne NE1 7RU, U.K.ORCID 0000-0003-3522-578X
Newcastle University · GB

Funding

Biotechnology and Biological Sciences Research Council BB/M018318/1Cancer Research UK 22095Cancer Research UK C1443/A12750Cancer Research UK C1443/A22095Medical Research Council MR/R023026/1Medical Research Council MR/T010789/1Wellcome Trust 062376Wellcome Trust 087961Wellcome Trust 094409
6 · The paper itself

Abstract

Claspin is an adaptor protein required for ATR-dependent phosphorylation of CHK1 during S-phase following DNA replication stress. Claspin expression is highly variable in cancer, with low levels frequently correlating with poor patient survival. To learn more about the biological consequences of reduced Claspin expression and its effects on tumorigenesis, we investigated mice with a heterozygous knockout of the Clspn gene. Claspin haploinsufficiency resulted in reduced female fertility and a maternally inherited defect in oocyte meiosis I cell cycle progression. Furthermore, aged Clspn+/- mice developed spontaneous lymphoid hyperplasia and increased susceptibility to non-alcoholic fatty liver disease. Importantly, we demonstrate a tumour suppressor role for Claspin. Reduced Claspin levels result in increased liver damage and tumourigenesis in the DEN model of hepatocellular carcinoma. These data reveal that Clspn haploinsufficiency has widespread unanticipated biological effects and establishes the importance of Claspin as a regulatory node controlling tumorigenesis and multiple disease aetiologies.

Indexed as

DNA ReplicationHaploinsufficiencyAnimalsAtaxia Telangiectasia Mutated ProteinsCarcinogenesisCell Cycle ProteinsCheckpoint Kinase 1FemaleFertilityHyperplasiaMicePhosphorylationAtaxia Telangiectasia Mutated ProteinsCell Cycle ProteinsCheckpoint Kinase 1ClapsinDNA replication and recombinationgenome integrityhepatocellular carcinomahyperplasiaoocyte

Identifiers

PMID36240068
PMCPMC9704638
OpenAlexW4306178548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.